Cancer patients get continued access to promising drug in safety study
NCT ID NCT05226871
First seen Dec 12, 2025 · Last updated May 15, 2026 · Updated 17 times
Summary
This study offers continued treatment with the cancer drug palbociclib to people who have already benefited from it in earlier Pfizer studies. It includes 35 adults with breast or head/neck cancer. The main goal is to monitor safety and track any serious side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Cancer Hospital Chinese Academy of Medical Science
Beijing, 100021, China
-
Department of Medicine, Faculty of Medicine Siriraj Hospital
Bangkok, 10700, Thailand
-
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Ratchathewi, Bangkok, 10400, Thailand
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, 64460, Mexico
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Mackay Memorial Hospital
Taipei, 10449, Taiwan
-
Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council
Dnipro, 49102, Ukraine
-
Municipal non-profit enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council
Ivano-Frankivsk, 76000, Ukraine
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
-
National Cheng Kung University Hospital
Tainan, 704302, Taiwan
-
Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center"
Chernivtsi, Chernivetska Oblast, 58013, Ukraine
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510000, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110167, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
UCSF Medical Center at Mission Bay
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.